Literature DB >> 17995968

Development and validation of a new instrument for the assessment of patient-defined benefit in the treatment of acne.

Matthias Augustin1, Christine Reich, Ines Schaefer, Ina Zschocke, Stephan Jeff Rustenbach.   

Abstract

BACKGROUND: Benefit assessment of drugs and medical products has become a legally established feature of medical research. A standardized assessment of benefits using scientifically sound and valid methods is essential.
OBJECTIVE: Development, validation and practical evaluation of an instrument to record patient benefit in treatment of acne. PATIENTS AND METHODS: In open interviews with n = 50 patients, possible benefits of the therapy from the patients' point of view were recorded. The item pool thus generated was reviewed by a panel of dermatologists, psychologists and patients and transferred to a 23-item questionnaire. This is used prior to therapy to assess patients' desired benefits and after therapy to record the perceived benefits. The therapy goals and the resulting benefits are then used to generate a weighted 'Patient Benefit Index' (PBI). The procedure has been tested for its validity and feasibility in n = 923 patients with acne.
RESULTS: Patients accepted the instrument and deemed it to be easily understandable. Additionally, the method proved itself to be internally consistent, constructively valid and sensitive to changes.
CONCLUSIONS: The Patient Benefit Index (PBI) is a valid and highly accepted practical instrument for recording patient benefit. The PBI permits an individualized, patient-weighted assessment of the benefits of acne therapy.

Entities:  

Mesh:

Year:  2007        PMID: 17995968     DOI: 10.1111/j.1610-0387.2007.06540.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  5 in total

1.  Cost-of-illness of chronic leg ulcers in Germany.

Authors:  Sandra Purwins; Katharina Herberger; Eike Sebastian Debus; Stephan J Rustenbach; Peter Pelzer; Eberhard Rabe; Elmar Schäfer; Rudolf Stadler; Matthias Augustin
Journal:  Int Wound J       Date:  2010-04       Impact factor: 3.315

2.  Feasibility of Using Qualitative Interviews to Explore Patients' Treatment Goals: Experience from Dermatology.

Authors:  Christine Blome; Kathrin von Usslar; Matthias Augustin
Journal:  Patient       Date:  2016-06       Impact factor: 3.883

3.  Development and Validation Features of the Patient Benefit Index for the Treatment of Allergic Rhinoconjunctivitis with Allergen Immunotherapy.

Authors:  Anna Langenbruch; Eike Wüstenberg; Hendrik Wolf; Matthias Augustin
Journal:  J Asthma Allergy       Date:  2022-05-11

4.  Development of a new tool for the assessment of patient-defined benefit in hospitalised older patients: the Patient Benefit Assessment Scale for Hospitalised Older Patients (P-BAS HOP).

Authors:  Maria Johanna van der Kluit; Geke J Dijkstra; Barbara C van Munster; Sophia De Rooij
Journal:  BMJ Open       Date:  2020-11-23       Impact factor: 2.692

5.  Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study.

Authors:  Pierre-Dominique Ghislain; Jo Lambert; Xuãn-Lan Lam Hoai; Tom Hillary; Pierre-Paul Roquet-Gravy; Michel de la Brassinne; Siegfried Segaert
Journal:  Adv Ther       Date:  2022-01-03       Impact factor: 3.845

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.